489 results on '"Ferrara, James L.M."'
Search Results
52. Immunologic response to cryoablation of breast cancer
53. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
54. ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death
55. Recommended Screening and Preventive Practices for Long-term Survivors after Hematopoietic Cell Transplantation: Joint Recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation
56. Critical role of host γδ T cells in experimental acute graft-versus-host disease
57. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease
58. Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease
59. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice
60. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation
61. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation
62. Graft-versus-host disease of the skin: life and death on the epidermal edge
63. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation
64. A Protective Gene for Graft-versus-Host Disease
65. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
66. Chapter 108 - Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses
67. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease
68. Pilot Study of Iodine-131–Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma
69. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation
70. Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
71. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
72. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony–stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation
73. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy
74. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect
75. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
76. Immunobiology of acute graft-versus-host disease
77. Role of interleukin-18 in acute graft-vs-host disease
78. Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease
79. Cytokines and the regulation of tolerance
80. Graft-versus-host disease
81. Essential Role for the p55 Tumor Necrosis Factor Receptor in Regulating Hematopoiesis at a Stem Cell Level
82. Differential roles of IL-1 and TNF-[small alpha, Greek] on graft-versus-host disease and graft versus leukemia
83. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
84. Acute Graft Versus Host Disease
85. Biomarkers in acute graft-versus-host disease: new insights
86. Tumor Necrosis Factor-[small alpha, Greek] Production to Lipopolysaccharide Stimulation by Donor Cells Predicts the Severity of Experimental Acute Graft-Versus-Host Disease
87. Interleukin-11 Promotes T Cell Polarization and Prevents Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation
88. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease
89. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
90. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
91. Graft-versus-Host Disease
92. Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease
93. Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease
94. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
95. In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation
96. Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease
97. Prevention of Transfusion-Associated Graft-Versus-Host Disease by Photochemical Treatment
98. Pathophysiologic mechanisms of acute graft-vs.-host disease
99. A Novel Role for the Semaphorin Sema4D in the Induction of Allo-responses
100. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.